EC Number |
Protein Variants |
Reference |
---|
2.3.2.26 | A349P |
mutant is defective in thioester formation |
757435 |
2.3.2.26 | A713P |
mutant is defective in thioester formation |
757435 |
2.3.2.26 | C1036A |
loss of ubiquitylation activity |
757186 |
2.3.2.26 | C2579G |
mutation in catalytic cysteine, loss of E3 ligase activity |
734247 |
2.3.2.26 | C716A |
mutation in catalytic cysteine. Cells transfected with C716A fail to accumulate securin with significant reduction in Mad2 level. Cell show a significant increase in cells displaying misaligned chromosomes, lagging chromosomes during mitotic exit, and multinucleation |
734350 |
2.3.2.26 | C922A |
dominant-negative active site mutant, predicted to result in an end point of 33% activity compared with wild-type. Addition of mutant C922A to the wild-type enzyme at saturating concentration inhibits wild-type NEDD4L to 30% limiting activity |
757205 |
2.3.2.26 | DELTA382-385 |
HECT domain mutant, capable of forming DTT-sensitive HECT-ubiquitin thioesters, defective in polyubiquitination |
757435 |
2.3.2.26 | DELTA383-385 |
HECT domain mutant, capable of forming DTT-sensitive HECT-ubiquitin thioesters, defective in polyubiquitination |
757435 |
2.3.2.26 | DELTA384-385 |
HECT domain mutant, capable of forming DTT-sensitive HECT-ubiquitin thioesters, defective in polyubiquitination |
757435 |
2.3.2.26 | E411Q |
slight decrease of affinity to human papilloma virus E6 oncogens |
728134 |